Airway Therapeutics

  • About Us
  • Pipeline
  • BPD
  • Respiratory & Inflammatory Diseases
  • News
  • Contact

New Company Formed to Take Cincinnati Children’s Lung Treatment Research to Premature Babies

June 3, 2011 By Airway Therapeutics

Airway Therapeutics LLC has been created to commercialize pulmonary therapy research developed at Cincinnati Children’s Hospital Medical Center and has received a $500,000 investment from CincyTech and Cincinnati Children’s Tomorrow Fund. The investments are part of a projected $1.2 million seed-stage funding round led by CincyTech. CincyTech and the Tomorrow Fund each invested $250,000 in the company, which is developing a new surfactant protein that would significantly improve lung function in premature infants. The company is headquartered at BioStart, the Cincinnati bioscience startup center located in Clifton, which is a previous investor in Airway.

Airway’s recombinant human Surfactant Protein-D (rhSPD) is based on 10 years of research by Jeffrey Whitsett, MD at Cincinnati Children’s Hospital Medical Center. Dr. Whitsett is chief of the Section of Neonatology, Perinatal and Pulmonary Biology at Children’s and one of Children’s most prolific researchers. The company is run by CEO Steve Linberg, Ph.D., who has more than 30 years of clinical research, drug development and biologic development experience.

Airway’s initial focus will be on the prevention of bronchopulmonary dysplasia (BPD) conjunction with the prevention and treatment of neonatal respiratory distress syndrome (nRDS) and in very premature infants. Normally, lungs mature to produce surfactant in the seventh month of gestation. Very premature infants (before 32 weeks gestation) have generally not yet developed lung surfactant to make the transition during birth from fluid-filled lungs to lungs that can easily expand to handle air movement. Administering surfactant to these very premature infants shortly after birth allows these infants to breathe. Currently there are three companies marketing surfactant in the U.S. for nRDS, but none is approved for BPD.

Surfactant Protein D is a normal component of animal (including human) surfactant but is missing in the available surfactants. Airway’s product, rhSP-D, would be added to existing surfactant prior to treating the very premature newborn, and has been shown in Dr. Whitsett’s lab to be useful in reducing lung inflammation, a condition associated with BPD.

The new investment will allow Airway to meet with the Food and Drug Administration within a few months to confirm their plans to begin developing rhSP-D in combination with an already-available surfactant, and then file an Investigational New Drug (IND) application within 15 months. “The company is already in discussion with one of the three surfactant manufacturers as a potential partner to produce the proposed new rhSP-D combination surfactant for use in treating these very premature infants,” Linberg said.

It is estimated that it will cost about $25 million to take the new combination product for the prevention of BPD in premature infants to market. Future goals include combining rhSP-D with a separate inhaled surfactant for the treatment for cystic fibrosis (CF).

CincyTech Executive-in-Residence Mike Venerable says Airway has the potential to bring to market a treatment that can save lives and improve child health.

“Within the U.S., it’s estimated that between 5,000 and 10,000 newborns develop bronchopulmonary dysplasia each year,” said Venerable. “rhSP-D will save babies that don’t survive today and radically improve the lives of millions of others.”

About Airway Therapeutics

Airway Therapeutics LLC was created to develop novel surfactant products based on 10 years of research conducted by Dr. Jeffrey Whitsett at Cincinnati Children’s Hospital Medical Center. The initial target applications include bronchopulmonary dysplasia (BPD) in premature infants and cystic fibrosis.

About CincyTech

CincyTech is a public-private venture development organization that invests in startup businesses in hightech industries in Southwest Ohio. With substantial support from Ohio Third Frontier and corporations, foundations, civic organizations and individuals here, it is stimulating the growth of venture-worthy companies in information technology, bioscience and advanced manufacturing.

Filed Under: News

logo

Airway Therapeutics, Inc

1200 Johnson Ferry Rd, Suite 300
Marietta, GA 30068

513.770.9630

  • Privacy

Sitemap

  • Home
  • About Us
  • Pipeline
  • BPD
  • Respiratory & Inflammatory Diseases
  • News
  • Contact
Copyright © 2015 Airway Therapeutics, Inc. All Rights Reserved.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.
Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT
MENU
  • About Us
  • Pipeline
  • BPD
  • Respiratory & Inflammatory Diseases
  • News
  • Contact